ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / JSPR
PLUR (34) SCLX (40) DYAI (31) ABOS (33) ⌘ Pro Terminal →

Jasper Therapeutics Inc. (JSPR) — RQD Stock Rating Cockpit

$0.51 -2.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.51

Jasper Therapeutics Inc. (JSPR) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $17.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on JSPR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is JSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Jasper Therapeutics Inc. (NASDAQ: JSPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.51 (-2.35% 1D, market cap $17.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, JSPR ranks #576 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does JSPR compare to PLUR and SCLX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), JSPR carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLUR (Pluri Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, JSPR leads on earnings multiple (N/A) while JSPR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for JSPR?
▼

Per JSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001788028), Jasper Therapeutics Inc. generated $234.9M in revenue (+10.0% YoY), -$76 in net income, and -$77.2M in free cash flow against $35.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.51 (-0.61%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (4)Whales (9)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
$3 Bull$0 Base$0 Bear
📬 FREE JSPR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JSPR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY JSPR SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
28
Grade E$0.50+0% Next Q
Q2 (-2Q)
31
Grade E$0.50+4% Next Q
Q3 (-1Q)
33
Grade E$0.52-1.9% Next Q
Current
36
Grade D-$0.51-8.3% Hist 90D α
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a JSPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While JSPR currently carries a cautious 36/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.59) and Max Pain ($0.54) forces dealer call-delta covering toward $2.54.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $JSPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “JSPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
44.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE9% OF RANGE
L: $0$0.51H: $2
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on JSPR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like JSPR
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JSPR)

  • ✓Walkthrough of JSPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
JSPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.48%⚡ TESTING RESISTANCE
2026-11-03O $0.53H $0.53L $0.51C $0.51VOL 396.1K
RES: $0.55SUP: $0.44SMA50: $0.59SMA200: $0.84
$2.00$1.54$1.08$0.63$0.17RES $0.55SUP $0.44$0.512026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JSPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JSPR Butterfly Map → + Track JSPR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +10.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on JSPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JSPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for JSPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JSPR)

Health Care Rank #576 of 1015 ⚔️ PLUR vs JSPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JSPR vs. PLUR, SCLX, DYAI, ABOS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Jasper Therapeutics Inc. (JSPR) ranks #576 by composite RQD confidence (36/100, grade D-) and #838 by equity capitalization ($17.3M). Within this direct 5-issuer industry benchmark cohort, JSPR leads on earnings valuation at N/A trailing P/E, while JSPR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with JSPR at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
JSPR ACTIVE
Jasper Therapeutics Inc.
D- 36/100 — — -35.0% -2.35% $17.3M Benchmark Subject
PLUR
Pluri Inc.
E 34/100 — 49.0% -35.0% -3.23% $16.7M /plur-vs-jspr →
SCLX
Scilex Holding Company
D- 40/100 — 96.0% -35.0% +1.08% $15.7M /sclx-vs-jspr →
DYAI
Dyadic International Inc.
E 31/100 — 24.9% -35.0% -1.10% $15.2M /dyai-vs-jspr →
ABOS
Acumen Pharmaceuticals Inc.
E 33/100 — — -35.0% +14.09% $15.2M /abos-vs-jspr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001788028 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jasper Therapeutics Inc. (JSPR) reported GAAP revenue of $234.9M (+10.0% vs. FY2024 revenue of $213.5M , and +21.8% cumulative change since FY2023) , GAAP net income of -$76, operating cash flow of -$77.2M, and free cash flow of -$77.2M (-23.3% YoY). On the balance sheet, JSPR closed FY2025 with $35.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $234.9M -$76 -$77.2M -$77.2M $35.8M —
FY2024 (FY) 2024-12-31 $213.5M -$71.3M -$62.6M -$62.6M $79.9M —
FY2023 (FY) 2023-12-31 $192.8M -$64.5M -$52.1M -$52.1M — —

3. JSPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Jasper Therapeutics Inc. (NASDAQ: JSPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.51 (-2.35% 1D, market cap $17.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, JSPR ranks #576 in composite RQD confidence.

How does JSPR compare to PLUR and SCLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), JSPR carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PLUR (Pluri Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, JSPR leads on earnings multiple (N/A) while JSPR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JSPR?

Per JSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001788028), Jasper Therapeutics Inc. generated $234.9M in revenue (+10.0% YoY), -$76 in net income, and -$77.2M in free cash flow against $35.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JSPR trading relative to its 50-day, 200-day, and 52-week technical levels?

JSPR last traded at $0.51 (-2.35% on volume of 452,333 shares), positioning the stock -13.56% below its 50-day simple moving average ($0.59) and -39.29% below its 200-day simple moving average ($0.84). Across its 52-week range of $0.31 to $2.42, JSPR sits at the 9.5% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.57).

Direct Sub-Reports: JSPR RQD Cockpit JSPR 12M Forecast JSPR Earnings & Move JSPR Dividends & DRIP JSPR Insiders & 13F JSPR Whale Options JSPR Profit Sankey JSPR News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

JSPR — Jasper Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Jasper Therapeutics Inc. (JSPR) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.51 (-2.35% 1D, market capitalization $17.3M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Jasper Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Its market capitalization is $0.0B on a rounded basis, consistent with the $17.7M figure in market data. Per the news wire, the company's clinical program includes vensobafusp alfa (KP104) in IgA Nephropathy, with a Phase 2 renal basket study cohort reported as having completed enrollment.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Jasper Therapeutics Inc. (JSPR) reported $234.9M in annual revenue (up from $213.5M in FY2024, +10.0% YoY) and -$76 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($192.8M revenue, -$64.5M net income) through FY2025, JSPR scaled operating cash flow to -$77.2M and free cash flow to -$77.2M, backed by $35.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.31 – $2.42 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), JSPR carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can JSPR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $234.9M and free cash flow of -$77.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is JSPR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

JSPR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Jasper Therapeutics Inc. (JSPR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to JSPR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

JSPR Bull vs. Bear Conversation Board — What's Your Call at $0.51?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON JSPR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on JSPR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $0.64 (+23.1%)
📌 Pinned Debate

Phase 2 IgAN cohort enrollment completed with interim data due by year-end 2026, a potential near-term clinical catalyst.

Here is why I am bullish on JSPR here at $0.52: Phase 2 IgAN cohort enrollment completed with interim data due by year-end 2026, a potential near-term clinical catalyst.. Compare JSPR's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $0.49 are getting bought.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 9/20 institutional whale-flow stock at $0.52 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.39 (-25.0%)
Spot @ $0.52

Operating losses widened to -$83.9M with FCF of -$77.2M against reported cash of $28.7M and a 0% FCF yield.

Sitting on the sidelines or leaning short JSPR above $0.52. Operating losses widened to -$83.9M with FCF of -$77.2M against reported cash of $28.7M and a 0% FCF yield.. Until Fundamental Cash Engine (4/20) and FCF yield (0.0%) inflect higher, upside is capped near $2.42.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%